Maxim Group Gives a Buy Rating to NLS Pharmaceutics (NLSP)

Maxim Group analyst Jason McCarthy assigned a Buy rating to NLS Pharmaceutics (NLSPResearch Report) yesterday and set a price target of $8.00. The company’s shares closed last Wednesday at $2.64, close to its 52-week low of $2.06.

According to TipRanks.com, McCarthy is a 5-star analyst with an average return of 18.6% and a 36.6% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Reviva Pharmaceuticals Holdings, Appili Therapeutics Inc Class A, and Brainstorm Cell Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for NLS Pharmaceutics with a $10.00 average price target, implying a 290.6% upside from current levels. In a report released yesterday, Brookline Capital Markets also initiated coverage with a Buy rating on the stock with a $12.00 price target.

See today’s analyst top recommended stocks >>

NLS Pharmaceutics’ market cap is currently $31.26M and has a P/E ratio of -10.00. The company has a Price to Book ratio of -3.63.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. The company focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company’s tangible assets are held in the United States.